Evolent Health officer plans 65,892-share sale

Evolent Health, Inc. (EVH) received a notice under Rule 144 that officer Daniel McCarthy plans to sell 65,892 shares of the company’s common stock through Merrill Lynch on or after August 26, 2026 on the NYSE.

Rhea-AI Filing Summary

Evolent Health, Inc. (EVH) received a notice under Rule 144 that officer Daniel McCarthy plans to sell 65,892 shares of the company’s common stock through Merrill Lynch on or after August 26, 2026 on the NYSE. The notice lists these as shares acquired from prior stock plan activity awards.

Key Figures

Shares proposed to be sold: 65,892 shares of common stock Aggregate market value: $327,476 Shares outstanding: 113,059,335 shares +3 more

6 metrics

Shares proposed to be sold 65,892 shares of common stock Proposed Rule 144 sale by Daniel McCarthy

Aggregate market value $327,476 Value of 65,892 shares proposed to be sold

Shares outstanding 113,059,335 shares Common stock outstanding for Evolent Health, Inc.

Stock plan activity on 02/21/2023 16,627 shares Common shares from issuer stock plan activity

Stock plan activity on 03/02/2023 6,225 shares Common shares from issuer stock plan activity

Stock plan activity on 03/01/2025 20,467 shares Common shares from issuer stock plan activity

Key Terms

Rule 144, stock plan activity, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock plan activity financial

"Common | 02/21/2023 | Stock plan activity | Issuer"

aggregate market value financial

"Common | Merrill Lynch ... | 65892 | 327476 | 113059335"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for EVH disclose?

The Form 144 discloses that officer Daniel McCarthy plans to sell 65,892 shares of Evolent Health, Inc. common stock under Rule 144, with sales expected to occur on or after August 26, 2026 through Merrill Lynch on the NYSE.

How many EVH shares are planned for sale under this Form 144?

The filing states a proposed sale of 65,892 shares of Evolent Health, Inc. common stock. These shares are reported as having been acquired through various stock plan activity transactions from the issuer.

What is the reported aggregate market value of the EVH shares in this Form 144?

The filing reports an aggregate market value of $327,476 for the 65,892 Evolent Health, Inc. shares proposed to be sold under Rule 144.

When may the EVH shares be sold according to the Form 144?

The notice indicates an approximate sale date of August 26, 2026 for the Evolent Health, Inc. common shares proposed to be sold under Rule 144 on the NYSE.

How many EVH shares are shown as outstanding in the Form 144?

The Form 144 lists 113,059,335 shares of Evolent Health, Inc. common stock as outstanding, providing context for the planned Rule 144 sale of 65,892 shares.

How were the EVH shares to be sold by Daniel McCarthy acquired?

The shares are tied to multiple stock plan activity entries from the issuer, including transactions on 02/21/2023, 03/02/2023, 02/22/2024, 03/01/2024, 03/02/2024, and 03/01/2025 with specified share amounts for each date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 05:43 PM EDT Accepted by SEC EDGAR 08/26/2026 - 05:42 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001946147
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Evolent Health, Inc.
SEC File Number
Address of Issuer	1812 N Moore Street, Suite 1705 Arlington VIRGINIA 22209
Phone	5713896000
Name of Person for Whose Account the Securities are To Be Sold	Daniel McCarthy
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K St NW Suite 800 Washington DC 20006	65892	327476	113059335	08/26/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/21/2023	Stock plan activity	Issuer			16627	02/21/2023	n/a
Common	03/02/2023	Stock plan activity	Issuer			6225	03/02/2023	n/a
Common	02/22/2024	Stock plan activity	Issuer			8069	02/22/2024	n/a
Common	03/01/2024	Stock plan activity	Issuer			7642	03/01/2024	n/a
Common	03/02/2024	Stock plan activity	Issuer			6862	03/02/2024	n/a
Common	03/01/2025	Stock plan activity	Issuer			20467	03/01/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel McCarthy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)